Literature DB >> 30582167

Risk and outcomes for second primary human papillomavirus-related and -unrelated head and neck malignancy.

Eric Adjei Boakye1,2, Paula Buchanan3, Leslie Hinyard3, Katie Stamatakis4, Nosayaba Osazuwa-Peters4,5,6, Matthew C Simpson6, Mario Schootman4, Jay F Piccirillo7.   

Abstract

OBJECTIVES/HYPOTHESIS: To 1) examine the characteristics of patients who develop second primary malignancies (SPMs) from an index human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and HPV-unrelated HNSCC and to 2) compare overall survival between those with HPV-related and HPV-unrelated index HNSCC among patients who develop SPM. STUDY
DESIGN: Retrospective cohort analysis.
METHODS: A retrospective study was conducted of 113,259 patients who were diagnosed with HNSCC from 2000 to 2014. SPM was defined as the first subsequent primary cancer occurring at least 2 months after index cancer diagnosis, and HPV-relatedness was based on whether patients' index HNSCC was potentially HPV-related or HPV-unrelated. Multivariable Fine and Gray (FG) competing-risks regression models were used to estimate factors associated with risk of SPM by HPV-relatedness. Among patients with SPM, an adjusted Cox proportional hazards (PH) regression model was used to assess the association between HPV-relatedness and survival.
RESULTS: Approximately 13,900 patients (12.3%) developed SPM. In the FG model, patients with HPV-unrelated HNSCC had a 15% higher risk of developing SPM (adjusted hazard ratio: 1.15, 95% confidence interval: 1.10-1.20) than those with potentially HPV-related HNSCC, but the same characteristics were associated with SPM development. In the Cox PH model, patients with SPM whose index HNSCC was HPV-unrelated had higher risk of death than those whose index HNSCC was potentially HPV-related (adjusted hazard ratio: 1.06; 95% confidence interval: 1.02-1.11).
CONCLUSIONS: Patients with HPV-unrelated HNSCC have a higher risk of SPM development than do those with HPV-related HNSCC. Effective secondary disease-prevention strategies should be established to improve long-term patient outcomes. LEVEL OF EVIDENCE: NA Laryngoscope, 129:1828-1835, 2019.
© 2018 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Epidemiology; Head and neck squamous cell carcinoma; Surveillance; and End Results (SEER); human papillomavirus; risk factor; second primary malignancy; survival

Mesh:

Year:  2018        PMID: 30582167     DOI: 10.1002/lary.27634

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.

Authors:  Eric Adjei Boakye; Maggie Wang; Arun Sharma; Wiley D Jenkins; Nosayaba Osazuwa-Peters; Betty Chen; Minjee Lee; Mario Schootman
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

2.  Prevalence of Transcriptionally Active HPV Infection in Tumor-Free Oropharyngeal Tissue of OPSCC-Patients.

Authors:  Vittoria Guarda; Lea Schroeder; Michael Pawlita; Kristian Ikenberg; Niels J Rupp; Wolfram Jochum; Sandro J Stoeckli; Dana Holzinger; Martina A Broglie
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

3.  Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer.

Authors:  Logan Corey; Julie Ruterbusch; Ron Shore; Martins Ayoola-Adeola; Michael Baracy; Alex Vezina; Ira Winer
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

4.  Differences in human papillomavirus (HPV) vaccine uptake by nativity status among men aged 18-34 years.

Authors:  Eric Adjei Boakye; Wenhui Zeng; Samuel Governor; Shreya Nagendra; Betelihem B Tobo; Matthew C Simpson; Nosayaba Osazuwa-Peters
Journal:  Prev Med Rep       Date:  2019-10-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.